BR112021007060A2 - compostos contendo deutério - Google Patents

compostos contendo deutério Download PDF

Info

Publication number
BR112021007060A2
BR112021007060A2 BR112021007060-5A BR112021007060A BR112021007060A2 BR 112021007060 A2 BR112021007060 A2 BR 112021007060A2 BR 112021007060 A BR112021007060 A BR 112021007060A BR 112021007060 A2 BR112021007060 A2 BR 112021007060A2
Authority
BR
Brazil
Prior art keywords
melflufen
deuterium
mol
compound
iii
Prior art date
Application number
BR112021007060-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of BR112021007060A2 publication Critical patent/BR112021007060A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021007060-5A 2018-10-18 2019-10-17 compostos contendo deutério BR112021007060A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GB1816998.7 2018-10-18
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
GB1909695.7 2019-07-05
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Publications (1)

Publication Number Publication Date
BR112021007060A2 true BR112021007060A2 (pt) 2021-07-20

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007060-5A BR112021007060A2 (pt) 2018-10-18 2019-10-17 compostos contendo deutério

Country Status (19)

Country Link
US (2) US12152087B2 (https=)
EP (1) EP3866931B1 (https=)
JP (2) JP7603199B2 (https=)
KR (1) KR102848971B1 (https=)
CN (1) CN112930214B (https=)
AU (1) AU2019362389B2 (https=)
BR (1) BR112021007060A2 (https=)
CA (1) CA3116198A1 (https=)
DK (1) DK3866931T3 (https=)
ES (1) ES2942468T3 (https=)
FI (1) FI3866931T3 (https=)
HU (1) HUE061801T2 (https=)
IL (1) IL282231B2 (https=)
MA (1) MA53904A (https=)
MX (1) MX2021004474A (https=)
PL (1) PL3866931T3 (https=)
SG (1) SG11202103726RA (https=)
WO (1) WO2020079165A1 (https=)
ZA (1) ZA202102492B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
ES3034388T3 (en) * 2021-06-01 2025-08-18 Synthon Bv Process for making melflufen or a salt thereof
JP2024524552A (ja) 2021-07-08 2024-07-05 オンコペプティデス エービー 多発性骨髄腫の治療に使用するためのメルフルフェン
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
DK2701720T3 (en) * 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
SMT202000058T1 (it) * 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. Vmat2のベンゾキノロン阻害剤
ES2901752T3 (es) * 2013-02-05 2022-03-23 Teva Pharmaceuticals Int Gmbh Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos
WO2015084622A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
CN110229159B (zh) 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Also Published As

Publication number Publication date
JP7603199B2 (ja) 2024-12-20
FI3866931T3 (fi) 2023-05-10
CN112930214A (zh) 2021-06-08
MX2021004474A (es) 2021-08-24
EP3866931B1 (en) 2023-02-15
IL282231A (en) 2021-05-31
MA53904A (fr) 2021-08-25
ES2942468T3 (es) 2023-06-01
KR102848971B1 (ko) 2025-08-21
US20250115637A1 (en) 2025-04-10
HUE061801T2 (hu) 2023-08-28
KR20210078487A (ko) 2021-06-28
EP3866931A1 (en) 2021-08-25
IL282231B2 (en) 2025-07-01
US12152087B2 (en) 2024-11-26
JP2024150488A (ja) 2024-10-23
CN112930214B (zh) 2025-05-16
US20210388024A1 (en) 2021-12-16
AU2019362389A1 (en) 2021-06-03
WO2020079165A1 (en) 2020-04-23
IL282231B1 (en) 2025-03-01
JP2022512736A (ja) 2022-02-07
PL3866931T3 (pl) 2023-06-19
DK3866931T3 (da) 2023-04-24
CA3116198A1 (en) 2020-04-23
SG11202103726RA (en) 2021-05-28
ZA202102492B (en) 2024-04-24
AU2019362389B2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
BR112021007060A2 (pt) compostos contendo deutério
ES2929526T3 (es) Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
EP3686184A2 (en) Ionizable compounds and compositions and uses thereof
US12152048B2 (en) Nitroxoline prodrug and use thereof
US12558337B2 (en) Formulations comprising melflufen
CN101268085B (zh) 用于硼中子俘获治疗的硼化合物
HK40048606A (en) Compounds containing deuterium
HK40048606B (en) Compounds containing deuterium
TW201922690A (zh) 環-amp反應元素結合蛋白的抑制劑
EA045396B1 (ru) Соединения, содержащие дейтерий
CN118005717A (zh) 一种用于制备谷氨酰胺拮抗剂的6-重氮-5-氧代-己酰胺衍生物
KR20250152557A (ko) 결정질 카바졸 유도체 및 이의 제조 방법
CN118406058A (zh) 一种替莫唑胺-阿魏酸的药物共晶体及其制备方法
TW202417007A (zh) 用於硼中子捕獲療法之小分子
EP3081556A1 (en) Amide compound and pharmaceutical comprising same
HK40047998A (en) Nitroxoline prodrug and use thereof
EA048956B1 (ru) Фармацевтическая композиция, содержащая мелфлуфен
CN111138282A (zh) 绿原酸l-精氨酸盐及其用途

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: ONCOPEPTIDES AB (SE)

B25A Requested transfer of rights approved

Owner name: ONCOPEPTIDES INNOVATION AB (SE)